Regeneron
REGENERON ANNOUNCES ENCOURAGING TOPLINE PHASE 2 DATA OF HIGH-DOSE AFLIBERCEPT IN WET AGE-RELATED MACULAR DEGENERATION TARRYTOWN, N.Y., Aug. 24, 2021 /PRNewswire/ — Phase 3 trials in wet AMD and diabetic macular edema…
REGENERON ANNOUNCES ENCOURAGING TOPLINE PHASE 2 DATA OF HIGH-DOSE AFLIBERCEPT IN WET AGE-RELATED MACULAR DEGENERATION TARRYTOWN, N.Y., Aug. 24, 2021 /PRNewswire/ — Phase 3 trials in wet AMD and diabetic macular edema…